Tunç Morova

This study uses longitudinal scRNA-seq to track neuroendocrine transdifferentiation in a prostate cancer model, identifying transcriptional changes and key regulators during treatment-induced NEPC progression.

This study uses longitudinal single-cell RNA sequencing to identify RUNX1T1 as a key regulator in the transition and maintenance of treatment-induced neuroendocrine prostate cancer.

The paper introduces a method to infer functional regulatory sites in enhancer sequences using STARR-seq data, showing it can identify local regulatory sites missed by global approaches.

The paper identifies breast cancer risk SNPs that overlap with estrogen receptor binding sites, showing their role in altering estrogen signaling through chromatin interactions.

This study develops snpSTARRseq, a high-throughput method to test non-coding variants from GWAS, showing 37% of prostate cancer risk loci alter enhancer activity.

The paper introduces CWAS, a method linking genetic variation to chromatin states, identifying novel prostate cancer risk loci and regulatory mechanisms not detectable by eQTLs.